<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947595</url>
  </required_header>
  <id_info>
    <org_study_id>DZD-2012</org_study_id>
    <nct_id>NCT01947595</nct_id>
  </id_info>
  <brief_title>Individualized Lifestyle Intervention in Subjects With Prediabetes</brief_title>
  <acronym>PLIS</acronym>
  <official_title>Prediabetes Lifestyle Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Diabetes-Center, Leibniz-Institut in Düsseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Endocrinology and Metabolic Diseases, Charité Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Institute of Human Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LMU München, medical clinic IV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The purpose of this prospective randomized multicenter intervention study is to determine
      whether in the prevention of Diabetes an intensified lifestyle intervention is superior to a
      conventional lifestyle intervention in high risk non-Responder subjects. Further, the
      intensive phenotyping to determine subgroups with an increased risk for diabetes enables an
      individualized prevention and therapy of type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study start with an intensive phenotyping at baseline (initial examination) to determine
      subjects with prediabetes. These high risk non-Responder are randomized in two arms
      (intensified vs normal lifestyle intervention)with equal number of subjects (n=250). The
      results are compared with each other at the end of the study.

      The low risk Responder are randomized in two arms (normal vs. once lifestyle intervention =
      control group) with equal number of subjects (n=250).

      After the screening at baseline the 12 month lifestyle intervention starts for lifestyle
      intervention groups. The different therapy groups are formed as described before. The
      subjects with intensified lifestyle intervention get 16 consultations, the subjects with
      normal lifestyle intervention get 8 consultations, the subjects of the control group get one
      consultation to learn more about a healthier lifestyle. During the whole study there is a
      continuous supervision from physician and nutritional advisers and the subjects have to
      document a nutrition and an exercise protocol as well as subjective measurements. At
      baseline, after 24 weeks and at follow up 1, 2 and 3 years later there is an elaborate
      metabolic characterization of all subjects (also the Responder groups) a 75 g venous oral
      glucose tolerance test (OGTT) as well as an analysis of the distribution of body fat
      confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT))</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity confirmed by 75 g oral glucose tolerance test (OGTT)</measure>
    <time_frame>one year</time_frame>
    <description>insulin resistance is calculated as follows:
Insulinogenic index (IGI) = (I30 - I0) / (G30 - G0)
ISIest= 10000/²√ ((G0 x I0) x ((G0+G30+G60+G90+G120)/5) x ((I0+I30+I60+I90+I120)/5))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion confirmed by 75 g oral glucose tolerance test (OGTT)</measure>
    <time_frame>one year</time_frame>
    <description>insulin resistance is calculated as follows:
Insulinogenic index (IGI) = (I30 - I0) / (G30 - G0)
ISIest= 10000/²√ ((G0 x I0) x ((G0+G30+G60+G90+G120)/5) x ((I0+I30+I60+I90+I120)/5))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of body fat confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>metabolic and genetic characterization to determine the risk of type 2 diabetes confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires, bio-electric impedance analysis (BIA)and ergospirometry</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>metabolic and genetic characterization to determine the non-response to lifestyle intervention confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires,BIA, ergospirometry</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1145</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>high risk non-responder, intensified lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high risk non-responder:
A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)&lt; 760)
B) insulin resistance (ISI-Matsuda &lt; 9,2)
C) elevated liver fat ( MRT &gt; 5,56%)
A+B or A+C or B+C or A+B+C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hight risk non responder, normal lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high risk non-responder:
A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)&lt; 760)
B) insulin resistance (ISI-Matsuda &lt; 9,2)
C) elevated liver fat ( MRT &gt; 5,56%)
A+B or A+C or B+C or A+B+C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Responder, normal lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Responder:
A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)&lt; 760)
B) insulin resistance (ISI-Matsuda &lt; 9,2)
C) elevated liver fat ( MRT &gt; 5,56%)
No A, only B or C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Responder, single lifestyle advice (control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Responder:
A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)&lt; 760)
B) insulin resistance (ISI-Matsuda &lt; 9,2)
C) elevated liver fat ( MRT &gt; 5,56%)
No A, only B or C</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>intensified lifestyle intervention</intervention_name>
    <description>physical activity 6 hours per week, 50% guided activity
recorded by an accelerometer (Aipermotion 440)
16 sessions per year with a lifestyle advisor
nutritional advice (target weight: 5% less, if BMI &gt; 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)</description>
    <arm_group_label>high risk non-responder, intensified lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>normal lifestyle intervention</intervention_name>
    <description>physical activity 3 hours per week
recorded by an accelerometer (Aipermotion 440)
8 sessions per year with a lifestyle advisor
nutritional advice (target weight: 5% less, if BMI &gt; 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)</description>
    <arm_group_label>hight risk non responder, normal lifestyle intervention</arm_group_label>
    <arm_group_label>Responder, normal lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Single lifestyle advice</intervention_name>
    <description>- Single Health care advice and lifestyle advice (30 minutes) at the beginning
recommend the individual target weight (5% less, if BMI 25&gt; kg/m²)</description>
    <arm_group_label>Responder, single lifestyle advice (control group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  impaired fasting glucose (IFG)

               -  fasting blood glucose 99-126 mg/dl

        and/or

          -  impaired glucose tolerance (IGT)

               -  75 g OGTT 120 minutes: 139-200 mg/dl

        Exclusion Criteria:

          -  current pregnancy or breastfeeding

          -  BMI &gt; 45 kg/m²

          -  Diabetes mellitus Typ 1 or 2

          -  serious disease e.g symptomatic coronary heart disease

          -  serious symptomatic malignant disease (weight loss &gt; 10% within the last 6 month)

          -  severe liver or kidney disease ( an increase in transaminases &gt; 3 times than the upper
             limit of the standardized range, GFR &lt; 50 ml/min/1,73m²)

          -  systemic infection (CRP &gt; 1 mg/dl)

          -  severe mental illness

          -  drug abuse

          -  treatment with steroids

          -  potentially incompliant subjects

          -  exclusion criteria for magnetic resonance tomography

               -  any kind of metal in or on the body:

                    -  cardiac pacemakers

                    -  prosthetic heart valves

                    -  metal prosthesis

                    -  magnetic implanted metallic parts

                    -  contraceptive coil

                    -  metal fragments/ grenade shrapnel

                    -  fixed braces

                    -  acupuncture needles

                    -  insulin pump

                    -  intraport etc.

                    -  Field strength &gt; 3 Tesla further tattoos, permanent make-up

               -  persons with limited thermosensory or heightened sensitivity to heating

               -  persons where cardiovascular disease cannot be ruled out by examination

               -  persons with heightened sensitivity to loud noise or diseases of the ear

               -  used closed whole body scanner: claustrophobia

        Additional for spirometry

          -  acute coronary syndrome

          -  higher cardiac arrhythmia

          -  decompensated heart failure

          -  acute carditis

          -  pulmonary embolism

          -  acute deep leg vein thrombosis ( phlebothrombosis)

          -  hyperthyroidism (TSH)

          -  hypokalemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Fritsche, Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Stefan, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Institut für Ernährungsforschung / Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Diabetes Zentrum</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München (TU Munich)</name>
      <address>
        <city>Munich</city>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helmholtz Zentrum München</name>
      <address>
        <city>Munich</city>
        <zip>85764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dzd-ev.de</url>
    <description>Click here for more information about this study: research in the DZD --&gt; klinische Studien</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>andreas fritsche</investigator_full_name>
    <investigator_title>Prof. Dr. med. Andreas Fritsche</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus type 2</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>lifestyle intervention</keyword>
  <keyword>body fat distribution</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

